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ABSTRACT 
Although group B Neisseria meningitidis is responsible for a 
significant amount of meningococcal meningitis, its capsular 
polysaccharide is precluded from the current vaccine because 
of its poor immunogenicity. This phenomenon is attributable to 
structural mimicry between the group B meningococcal poly- 
saccharide (GBMP) and human tissue antigens. One simple 
way to avoid this problem is to use as a vaccine a synthetic 
N-propionylated (NPr) form of the GBMP, which when conju- 
gated to tetanus toxoid (TT), induces, in mice, high titers of 
bactericidal antibodies against all group B meningococci. For- 
tuitously, the major population of NPr GBMP-specific antibod- 
ies, even though not cross-reactive with the GBMP, contains 
all the protective activity. Only a minor population of GBMP 
cross-reactive antibodies are produced, but even the level of 
these antibodies can be significantly reduced by adjuvant 
manipulation. Thus the NPr GBMP mimics a highly conserved 
capsule-associated epitope that could be the basis of a poten- 
tial vaccine against group B meningitis. To further define this 
protective epitope, a series of GBMP-specific monoclonal anti- 
bodies of the IgG isotype were produced using an (NeuPr)=,,- 
TT conjugate vaccine. Unlike GBMP-specific antibodies, which 
recognize epitopes found only on the extended helical form, 
some of those secreted by the NPr GBMP-specific clones were 
also able to recognize short (random coil) segments of the NPr 
GBMP However, only those antibodies specific for the extended 
helical epitopes were protective as defined by bactericidal 
assays or passive protection experiments. 
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Neisseria meningitidis is a human pathogen of world- 
wide signitlcance. Despite the success of current vaccines 
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composed of the meningococcal groups A, C, W-135, 
and Y capsular polysaccharides, they still have serious 
limitations. First, all the polysaccharides induce an inad- 
equate response in infants, I>2 the section of the popula- 
tion most susceptible to disease. Second, despite the fact 
that group B N meningitidis is the most prevalent 
pathogen, even being responsible for about 70% of cases 
of meningococcal meningitidis in developed countries,* 
its capsular polysaccharide is precluded from the above 
vaccine because of its poor immunogenicity in both 
infants and adults.3 Serologic evidence accumulated from 
animal experiments has indicated that the first limitation 
can probably be overcome by enhancing the immuno- 
genic&y of the polysaccharides. This can be achieved by 
covalently linking them to protein carrier molecules to 
form a new generation of glycoconjugate vaccines.* Such 
vaccines composed of groups A and C polysaccharide- 
protein conjugates are now undergoing preliminary 
human trials.5 However conjugation technology alone 
will not overcome the second limitation of the poor 
immunogenic&y of the group B meningococcal polysac- 
charide (GBMP), because even when conjugated to pro- 
tein carriers, the resultant glycoconjugate vaccines fail 
to give significant immune responses4a6 This phenome- 
non is probably attributable to structural mimicry 
between the GBMP and human tissue antigens.7zs 
Currently there is no vaccine against group B meningo- 
coccal meningitis, and most efforts to develop an effective 
vaccine have focused on alternative surface-exposed com- 
ponents, such as outer membrane proteins (OMPs) and 
lipopolysaccharides (LPSs). 9~1o Many problems associated 
with the development of vaccines based on these com- 
ponents have been identified, not the least of which is 
their intrinsic antigenic diversity. Variable and suboptimal 
efficacies in a number of human trials involving the use of 
outer membrane complex vaccines containing outer mem- 
brane proteins have been attributed to their antigenic diver- 
sity.i1-13 Furthermore, these vaccines have also proven to 
be ineffective in infants.12 To minimize serotype diversity, 
these vaccines will need to be composed of multiple 
OMPs, but this in turn will create problems of protein and 
LPS overload. One highly sophisticated method to achieve 
the above goal is to recombinantly construct multivalent 
OMP strains,‘* and this promising approach is being devel- 
oped. Iron-regulated proteins have also recently been stud- 
ied as potential candidates for a group B meningococcal 
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vaccine. These transferrin-binding proteins have been 
shown to elicit protective and bactericidal antibodies in 
animal~,‘~~‘~ but again, they exhibit considerable antigenic 
heterogeneity, l7 the extent of which has not been fully 
determined. 
The development of an LPS-based vaccine against 
group B meningococcal meningitis is also being pur- 
sued,i8 but has met with only marginal success to date. 
Although many different problems have been encoun- 
tered in the development of these vaccines, the antigenic 
diversity of the meningococcal LPS also remains a major 
challenge.‘* The source of this diversity lies in the con- 
siderable structural variability manifested by the oligosac- 
charide moieties of the LPS.19 One method of simplifying 
an LPS-based vaccine would be to use minimal inner core 
oligosaccharide structures, common to all immunotypes, 
to construct a broadly cross-reactive oligosaccharide-pro- 
tein conjugate vaccine. 2o Unfortunately this approach has 
met with little success to date, particularly in the ability 
of these vaccines to induce bactericidal antibodies.” 
Because the GBMP is the only conserved antigenic 
structure on the surface of group B meningococci, a poly- 
saccharide-based vaccine would be the vaccine of choice, 
provided its poor immunogenicity could be overcome. A 
novel approach to achieve this goal is to chemically mod- 
ify the GBMP prior to its conjugation to a protein carrier, 
to form a synthetic vaccine with enhanced immuno- 
gemcity of its g&co component.21~22 A glycoconjugate vac- 
cine composed of NPr GBMP conjugated to tetanus 
toxoid (TT) has been shown to have considerable poten- 
tial as a vaccine against group B meningococcal menin- 
gitis, and this type of synthetic vaccine is the subject of 
this review. 
IMMUNOLOGIC PROPERTIES OF THE GROUP B 
MENINGOCOCCAL POLYSACCHARIDE 
The poor immunogenic&y of the GBMP precludes its 
inclusion in the current meningococcal vaccine.3 
Although group B meningococci are able to produce low 
levels of GBMP-specific antibodies in animals and humans, 
these antibodies are almost exclusively of the IgM iso- 
type, and of relatively low affinity.23 Although the co- 
valent coupling of the GBMP to protein carriers results 
in enhanced polysaccharide-specific antibody levels, 
including antibodies of the IgG isotype, these levels are 
generally low and no bactericidal activity has been 
reported.*b These results indicate that it is unlikely that 
protein conjugates of the GBMP will be of importance in 
the production of vaccines against meningitis caused by 
group B N meningitidis. Even if this manipulation had 
succeeded in producing a good response, the issue of 
whether immune tolerance would be broken would also 
have to be addressed before such a vaccine could be 
sanctioned for human use. 
It is probable that molecular mimicry is involved in 
the poor immunogenic&y of the GBMP because the cap- 
sule of group B N meningitidis, which is identical to that 
of Escherichia coli Kl, consists of a homopolymer of 
c-w2-+84inked N-acetylneurannm . ‘c acid residues2* and sim- 
ilar structures have been identified in human tissue anti- 
gens.7,8,zj The extent of human tolerance to the GBMP 
is, therefore, explicable in terms of its precise structural 
homology to the above tissue antigens. The structures 
of these human tissue antigens range from shorter frag- 
ments of o2+8-polysialic acid, such as the monomeric 
and dimeric fragments found in mammalian ganglio- 
sides 25 to longer fragments carried by glycoproteins 
involved in neural cell adhesion and other tissues includ- 
ing human tumors. ‘s8 These latter polysialic chains are 
long, consisting of up to 12 contiguous sialic acid 
residues, and have been identified in lengths in excess of 
55 contiguous sialic acid residues in the glycoproteins of 
human neuroblastoma cells.’ For the most part the poly- 
sialosyl chains on neural cell adhesion molecules are 
developmental (fetal) antigens, whose length is reduced 
rapidly during development, although there is evidence 
that they persist even in adult mammalian tissue.26 
Despite its poor immunogenicity, GBMP-specific anti- 
bodies can be produced in special circumstances. Hyper- 
immunization of a horse with group B meningococci has 
produced high levels of GBMP-specific IgM antibodies,*’ 
and using similar immunization procedures, murine mono- 
clonal antibodies of the same specificity have been pro- 
duced.28,29 The potential of some of the latter antibodies 
to be protective against group B meningococci and E. 
coli Kl has been demonstrated in passive protection stud- 
ies and opsonophagocytic assays.29 Human transformed 
cell lines producing protective GBMP-specific antibodies 
have been described,30 and a human macroglobulin (IgM 
NOV) with the same specificity also has been reported.31 
All the above GBMP-specific antibodies were of the IgM 
isotype with the exception of mAb 735 produced in an 
autoimmune New Zealand black (NZB) mouse system, 
which was of the IgG isotype.28 Thus antibodies to 012-%3- 
polysialic acid can be produced using aggressive vacci- 
nation schedules with whole organisms as the 
immunogen. However, the best approach to make a vac- 
cine based on the GBMP probably resides in its chemi- 
cal manipulation. 
EXTENDED HELICAL EPITOPE OF GROUP B 
MENINGOCOCCAL POLYSACCHARIDE 
The presence of a conformational epitope in or2+&poly- 
sialic acid was initially hypothesized to explain the inabil- 
ity of oligomer fragments of up to five sialic acid residues 
to inhibit the binding of the GBMP to a homologous horse 
antibody32 To date it has been established that all a2+3- 
polysialic acid-specific antibodies require an unusually 
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long segment of cr2+8polysialic acid for binding to 
OCCLU.~~-~~ It has been proposed that antibodies recognize 
an extended helical form of this polysaccharide and that 
a minimum of about nine residues is required to form this 
extended helical epitope.33-35 The validity of this hypoth- 
esis was further strengthened by the identification of a 
common length-dependent epitope responsible for the 
cross-reaction of a2-Spolysialic acid and poly (A) with 
a human monoclonal macroglobulin (IgM NOV),31 and the 
known propensity of poly (A) to form helices of n = S- 10. 
Because these two biopolymers share no common struc- 
tural features, the cross-reaction is thought to be due to 
a common epitope composed of a similar helical spatial 
arrangement of negative charges. This is supported by 
the fact that o2+8sialooligosaccharides exhibit identical 
inhibitory properties no matter whether poly (A) or the 
GBMP is used as the binding antigen to IgM N0Y36 
By means of potential energy calculations and 
nuclear magnetic resonance (NMR) it has been shown 
that, although mostly random coil in nature, clr2+&poly- 
sialic acid can adopt extended helical conformations 
where n = 9.37 It has also been demonstrated that the 
stability of this extended helical conformation is depen- 
dent on its carboxylate groups.” Experiments to obtain 
unequivocal proof of the existence of this extended heli- 
cal epitope have been carried out in which it was 
attempted to co-crystallize ol(2+3)-linked oligomers of 
n = 10 with a Fab fragment of mAb 735; unfortunately 
these have not been successful to date. However, con- 
vincing evidence was obtained when the Fab fragment 
of mAb 735 was crystallized in the absence of hapten 
and subjected to x-ray diffraction analysis.39 The binding 
site consisted of an unusually long groove, which was 
bimodal in that it underwent a striking reversal in shape 
and charge distribution along the interface between 
heavy and light chains. With only minor adjustments, the 
extended helical model proposed by Brisson et al,“’ when 
modeled into the binding site, had a shape and charge dis- 
tribution that was complementary to the Fab from mAb 
735 (Figure 1). At least eight residues are accommodated 
in the site, the helical twist of a(2-+3)-polysialic acid 
positioning the appropriate functional groups for binding 
to the bimodal site. 
From binding studies that have been reported on dif- 
ferent GBMP-specific antibodies, all are specific for the 
extended helical epitope.33-3S Because conformational 
studies indicate that this epitope is only a minor con- 
tributor to the total number of epitopes formed by (w2+& 
polysialic acid,38 the dominance of antibodies with a 
specificity for this less populous epitope must be the 
result of immunologic selection. The reluctance of the 
immune system to produce antibodies associated with 
the more populous random coil form of the pofymer 
probably occurs because these epitopes are conforma- 
tionally similar to the shorter sialyloligomers. These lat- 
ter structures are also present in human tissue,25 and the 
Figure 1. Stereoview of the fit of the helical model of a(2-+8)-linked 
sialic acid to the binding surface of Fab mAb 735. 
production of antibody to them, rather than to the 
extended helical form of ol2+&polysialic acid, is even 
more stringently avoided. 
CHEMICAL MODIFICATION OF THE GROUP B 
MENINGOCOCCAL POLYSACCHARIDE 
The failure of GBMPprotein conjugates to provide satis- 
factory levels of protective antibody against group B 
meningococci prompted interest in the further chemical 
modification of cy2-Spolysialic acid prior to its conju- 
gation. One modification that could be made without 
disturbing the required helical conformation of (-w2-+8- 
polysialic was to replace the N-acetyl groups of its sialic 
acid residues with N-propionyl (NPr) groups.21,22 The 
modified polysaccharide was then conjugated to TT, and 
the synthetic glycoconjugate vaccine was evaluated in 
mice.‘l The NPr GBMP-‘IT conjugate, when administered 
with Freund’s complete adjuvant (FCA), was able to 
induce high titers of NPr GBMP-specific antibodies in 
mice, which were highly bactericidal for group B 
meningococci and passively protective against both group 
B meningococci and E. coli Kl .‘l,*O Despite the fact that 
the NPr GBMP-TT conjugate was able to induce in mice 
higher titers of GBMP cross-reactive IgG antibodies than 
the homologous GBMP-TT conjugate, this GBMP-specific 
antibody was not protective. *O,*l The data in Table 1 show 
that, although group B meningococci were able to absorb 
out the protective antibodies from the antisera, the 
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Table 1. Bacterial Titers and Passive Protective Efficiency of Anti-NPr-GBMP Serum Absorbed with Group B Meningococcal 
Polysaccharide 
Radioactive Antigen Mouse Bacteremia Viable Bacterial 
Binding Assay Counts per mL of Bloodt 
Serum * GBMP PlPr-GBMP Bactericidal Titer 3h 5h 
Anti-NPr GBMP (non-absorbed) 500 77 512 0 (100) 240 (91) 
$tiia;r GBMP* (absorbed with GBMP) 0 73 512 0 (100) 24 (99) 
0 0 <4 2200 2744 
*Final dilution 1 :I 0; t% reduction compared to mice that received normal mouse serum at time after challenge; $500 UL of serum absorbed with 250 PL of GBMP (1 
mg/mL) for 4 days at 4°C; spercentage of binding to 3H-labeled antigens. 
purified GBMP capsule was unable to remove any of the 
bactericidal or passively protective antibodies. Thus, it 
was demonstrated that NPr GBMP-specific antibodies con- 
sist of two distinct populations, one of which (minor 
population) cross-reacts with the GBMP and is not pro- 
tective, whereas surprisingly, the other, larger population 
of GBMP non-cross-reactive antibodies contains all the 
protective antibodies. *l This evidence indicates that the 
NPr GBMP mimics a different epitope on the surface of 
group B meningococci and E. coli Kl than is presented 
by the purified GBMP *L*’ Recently, this epitope has been 
located in the capsular layer of both group B meningo- 
cocci and E. coli Kl by electron microscopy Therefore, 
NPr GBMP-protein conjugates are ideal vaccine candi- 
dates, but it is probably realistic to suppose that their 
acceptance will depend on being able to control the 
induction of ol2+8-polysialic acid-specific antibody, even 
though it has not yet been established whether these 
cross-reactive antibodies will in fact have any deleterious 
effects in either mice or humans. Certainly, it has been 
clearly demonstrated that patients suffering from group 
B meningitis mount a humoral response (mostly IgM) to 
the cx2+&polysialic acid capsule of the bacteria, and that 
this antibody is protective.43 
One practical method of diminishing the production 
of GBMP cross-reactive antibodies is to vary the adjuvant 
formulations used with the NPr GBMP-TT conjugate. This 
was established from data obtained from an experiment 
in which groups of mice were immunized with the same 
NPr GBMP-‘IT vaccine, using different adjuvants in the 
vaccine formulations (Figure 2). Because all the gly- 
coconjugate vaccines induced only marginal titers of IgM 
antibodies, only the titers of IgG antibodies were quan- 
tified. The control vaccine, in which no adjuvant was 
used, produced very low titers of NPr GBMP-specific anti- 
body that was not protective and did not cross-react with 
the GBMF! Therefore, the immune response to this vac- 
cine would need to be considerably enhanced before it 
could be of utility. By adjuvanting NPr GBMP-TT with 
alum, the immune response could be enhanced, but only 
with a concomitant increase in cross-reactivity to the 
GBMF! This vaccine preparation produced a predominate 
IgG, antibody response, which although not bactericidal, 
was still able to passively protect mice from challenge 
with live group B meningococci. From the results of pre- 
vious experiments that indicated that GBMP cross-reac- 
tive antibodies induced by NPr GBMP-‘IT (!XA) were not 
protective (see Table l), it is unlikely that the 8% of cross 
reactive antibodies produced by the identical alum adju- 
vanted conjugate could be responsible for this protection 
(see Figure 2). 
To achieve bactericidal activity in mice, an isotype 
switch from IgG, to IgG, or IgG, is required, and this can 
be achieved by more potent adjuvants (see Figure 2). In 
agreement with previous experiments,42 this isotype 
switch was accomplished by the use of FCA, which when 
used with the NPr GBMP-TT conjugate, induced high 
titers of highly bactericidal antibodies, of which 23% 
were shown to be cross-reactive with the GBMP (see Fig- 
ure 2). In agreement with previous absorption experi- 
ments, it is unlikely that the latter cross-reactive antibody 
is protective against group B meningococci. Fortunately 
FCA is not appropriate for human use, and the goal of 
producing high titers of NPr GBMP-specific bactericidal 
antibodies with a significant reduction in the amount of 
GBMP cross-reactive antibody can still be achieved using 
other adjuvants. For example the use of RIBI’s monophos- 
Saline AI Freund’s RIBI’S 
WV 
Propionyl GBMP 1,810 76,430 339,630 710.800 
GBMP 0 cm 78,310 1,690 
Adjuvant System 
Figure 2. Cross-reactivity of antisera to NPr GBMP-lT using differ- 
ent adjuvants. Percentage cross-reaction is defined as the ratio of Iv- 
acetyl to N-propionyl GBMP ELISA titers. 





Table 2. Biologic Activity of Selected Monoclonal Antibodies to N-Propionyl Group B Meningococcal Polysaccharide* 
lmmunogen lsotype Epitope Bactericidal Activity+ Passive Protection* 
(NeuPr),,-ll Ig%, Short No activity at ~600 ug/mL No clearance 
(NeuPr),,-iT W, Extended No activity at ~600 ug/mL 100 ug: 97% clearance 
50 ug: 85% clearance 
10 ug: 25% clearance 
2 ug: 57% clearance 
(NeuPr),,-Tr I@%, Extended 1 ug/mL 100 ug: 99% clearance 
50 ug: 94% clearance 
10 ug: 92% clearance 
*Representative sample of 34 mAbs expressing similar physical and serologic properties; tamount of antibody for 50% killing of IV. mefkgitidis serogroup B (strain 
80-165 B:2b:P.i); *unless otherwise noted, mice were passively transferred with 50 ug of mAb and challenged with N. menhgitidis serogroup B (strain 80-165 
B:2b:P.I). The percentage of clearance was calculated relative to negative control mice. 
pholipid (MPL) adjuvant in conjunction with NPr GBMPTT 
gives even higher titers of bactericidal antibodies than 
obtained using FCA with a significant diminution (over 
lOO-fold) in GBMP cross-reactive antibody (see Figure 2). 
PROTECTIVE EPITOPE OF NPr GROUP B 
MENINGOCOCCAL POLYSACCHARIDE 
Because cross-reactive antibodies to the GBMP induced 
by NPr GBMP-TT are not protective, defining the nature 
of the epitope responsible for the production of 
non-cross-reactive NPr GBMP-specific antibody is of the 
utmost importance. The close structural resemblance of 
the NPr GBMP with the GBMP would suggest that the epi- 
tope is still closely associated with the GBMP even though 
the GBMP does not bind to bactericidal NPr GBMP-spe- 
cific antibodies.41,42 This evidence is also consistent with 
the fact that two different species of bacteria (group B 
meningococci and E. coli Kl), having capsular o2+8- 
polysialic acid as their only common surface antigen, 
were both able to absorb the bactericidal antibodies from 
an NPr GBMP-TT mouse antiserum.41 To characterize this 
protective non-cross-reactive epitope more fully, a series 
of NPr GBMP-specific mAbs were produced by immu- 
nizing Balb C mice with NPr GBMP-TI (RIBI). The clones 
were screened with both NPr GBMP-HSA and GBMP-HSA 
conjugates to select clones whose mAbs did not cross- 
react extensively with the GBMP Furthermore, by using 
a truncated (Neu5Pr)-HSA conjugate in the screening pro 
cedure, it was also possible to isolate a few clones that 
were also able to bind to short internal regions of the 
NPr GBMP Thus, in contrast to the GBMP where it has 
not been possible to detect antibodies specific for short 
regions of the polymeq3j NPr GBMP induces antibodies 
to both conformational extended helical and conven- 
tional short epitopes. These epitopes have their origins 
in the internal extended helical and random coil forms 
of the NPr GBMP, respectively, and reflect the intrinsic 
flexibility of the NPr GBMP.38 
For the sake of brevity and pertinence to the fol- Figure 3. End-on view of the identical helices (n = 9) that can be 
lowing discussion, three mAbs were selected from those formed by both the GBMP (/eff) and the NPr GBMP (right). 
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having no detectable cross-reaction with the GBMP (Table 
2). They are broadly representative of mAbs obtained 
from other clones. Two important conclusions can be 
drawn from the data in Table 2. The first is that whereas 
IgG, antibody (mAb 13AS) is not bactericidal, it confers 
good passive protection in mice challenged with live 
group B meningococci. Thus, bactericidal activity may 
not be the only mechanism of protection against group 
B meningococci. Second, a comparison of mAbs 6B9 and 
13D9 indicates that although both are of the IgGza iso- 
type, and thus potentially bactericidal, only 13D9 was 
bactericidal for group B meningococci. Thus, it can be 
postulated that only mAbs with a specificity for the 
extended helical form of the NPr GBMP are bactericidal, 
and that the same conformational restriction also applies 
to all mAbs of the IgG, isotype in terms of their ability 
to passively protect in a mouse challenge model. That 
the NPr GBMP can adopt the same extended helical form 
as the GBMP (Figure 3) has been confirmed by high res- 
olution NMR studies and potential energy calculations.38 
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